Forrester D L, Barr H L, Fogarty A, Knox A
Division of Respiratory Medicine, Clinical Sciences Building, University of Nottingham, City Hospital Campus, Nottingham, NG5 1PB, United Kingdom.
Division of Public Health and Epidemiology, Clinical Sciences Building, University of Nottingham, City Hospital Campus, Nottingham, United Kingdom.
Pediatr Pulmonol. 2017 Apr;52(4):467-471. doi: 10.1002/ppul.23650. Epub 2017 Jan 9.
sTREM-1 (soluble triggering receptor expressed on myeloid cells-1) is a novel inflammatory marker that may be of clinical use in cystic fibrosis (CF). Dysregulation of the TREM pathway has been demonstrated in other inflammatory diseases and modulation in animal models has therapeutic benefit. We hypothesised that sTREM-1 could act as a biomarker of disease in cystic fibrosis.
Plasma from 17 patients with CF (stable and pre and post pulmonary exacerbation) and eight healthy volunteers was analyzed for sTREM-1 and proteases (matrix metalloproteinase-8 (MMP-8), MMP-9, and human neutrophil elastase HNE).
sTREM-1 Levels were elevated in stable CF subjects compared to controls (148 pg/ml (130-160) [median(IQR)] vs. 87 (55-118) (P < 0.01)) but were not further increased during pulmonary exacerbation nor decreased after antibiotic treatment in CF. Protease levels were increased in CF plasma compared to controls: MMP-8 = 3.1 ng/ml (1.5-7.6) vs. 0.3 (0.18-0.53) (P < 0.01) (Wilcoxon); MMP-9 = 170 ng/ml (124-282) vs. 49 (39-90) (P < 0.01); HNE = 30.2 ng/ml (22.7-30.9) vs. 17.5 (11.2-22.2) (P < 0.05). sTREM-1 correlated positively with protease levels lnMMP-8 r = 0.55 (P = 0.08), lnMMP-9 r = 0.61(P < 0.05), lnHNE r = 0.35 (P < 0.05).
sTREM-1 is constitutively elevated in CF and positively correlates with protease levels. Modulation of this pathway may be of therapeutic benefit to patients with CF. Pediatr Pulmonol. 2017;52:467-471. © 2017 Wiley Periodicals, Inc.
可溶性髓系细胞触发受体-1（sTREM-1）是一种新型炎症标志物，可能在囊性纤维化（CF）的临床应用中具有价值。TREM途径的失调已在其他炎症性疾病中得到证实，并且在动物模型中的调节具有治疗益处。我们假设sTREM-1可作为囊性纤维化疾病的生物标志物。
分析了17例CF患者（病情稳定、肺部加重期前后）和8名健康志愿者血浆中的sTREM-1和蛋白酶（基质金属蛋白酶-8（MMP-8）、MMP-9和人中性粒细胞弹性蛋白酶HNE）。
与对照组相比，稳定期CF患者的sTREM-1水平升高（148 pg/ml（130 - 160）[中位数（四分位间距）] 对87（55 - 118）（P < 0.01）），但在肺部加重期未进一步升高，CF患者经抗生素治疗后也未降低。与对照组相比，CF患者血浆中的蛋白酶水平升高：MMP-8 = 3.1 ng/ml（1.5 - 7.6）对0.3（0.18 - 0.53）（P < 0.01）（Wilcoxon检验）；MMP-9 = 170 ng/ml（124 - 282）对49（39 - 90）（P < 0.01）；HNE = 30.2 ng/ml（22.7 - 30.9）对17.5（11.2 - 22.2）（P < 0.05）。sTREM-1与蛋白酶水平呈正相关：lnMMP-8的r = 0.55（P = 0.08），lnMMP-9的r = 0.61（P < 0.05），lnHNE的r = 0.35（P < 0.05）。
CF患者的sTREM-1持续升高，且与蛋白酶水平呈正相关。调节该途径可能对CF患者具有治疗益处。《儿科肺脏病学》。2017年；52：467 - 471。© 2017威利期刊公司。
